Mechanism and Potential Therapeutic Strategies Based on PRMT5 in Chemotherapy-Induced Drug Resistance in Non-Small Cell Lung Cancer

Zheng Zhang; Yi Liu

doi:10.62051/ijphmr.v1n3.09

Authors

Zheng Zhang
Yi Liu

DOI:

https://doi.org/10.62051/ijphmr.v1n3.09

Keywords:

NSCLC, Drug Resistance, PRMT5

Abstract

As a malignant tumor with high morbidity and mortality in the world, the treatment of non-small cell lung cancer is still facing great challenges. Although new breakthroughs have been made in recent years and great progress has been made in chemotherapy and targeted therapy, the five-year survival rate of most NSCLC patients is still at a low level. The emergence of drug resistance is one of the important factors affecting the therapeutic effect and survival rate of patients. PRMT5 (protein arginine methyltransferase 5), as a type II arginine methyltransferase, plays an important role in cancer cell proliferation, differentiation, apoptosis and tumorigenesis. At present, people pay more and more attention to the research on the mechanism of PRMT5 in tumor drug resistance. In this review, we summarize the mechanism of PRMT5 in chemotherapy resistance of non-small cell lung cancer and discuss potential strategies to avoid or overcome chemotherapy resistance.

References

Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC [J]. Lung Cancer, 2011, 71(1): 3-10.

Niederst M J, Sequist L V, Poirier J T, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer [J]. Nat Commun, 2015, 6: 6377.

Sequist L V, Waltman B A, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors [J]. Sci Transl Med, 2011, 3(75): 75ra26.

Bluemn E G, Coleman I M, Lucas J M, et al. Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling [J]. Cancer Cell, 2017, 32(4): 474-489.e476.

Zou M, Toivanen R, Mitrofanova A, et al. Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer [J]. Cancer Discov, 2017, 7(7): 736-749.

Kim H, Ronai Z A. PRMT5 function and targeting in cancer [J]. Cell Stress, 2020, 4(8): 199-215.

Barczak W, Jin L, Carr S M, et al. PRMT5 promotes cancer cell migration and invasion through the E2F pathway [J]. Cell Death Dis, 2020, 11(7): 572.

Checa-Rodríguez C, Cepeda-García C, Ramón J, et al. Methylation of the central transcriptional regulator KLF4 by PRMT5 is required for DNA end resection and recombination [J]. DNA Repair (Amst), 2020, 94: 102902.

Zhu F, Rui L. PRMT5 in gene regulation and hematologic malignancies [J]. Genes Dis, 2019, 6(3): 247-257.

Li M, An W, Xu L, et al. The arginine methyltransferase PRMT5 and PRMT1 distinctly regulate the degradation of anti-apoptotic protein CFLAR(L) in human lung cancer cells [J]. J Exp Clin Cancer Res, 2019, 38(1): 64.

Gilson P, Drouot G, Witz A, et al. Emerging Roles of DDB2 in Cancer [J]. Int J Mol Sci, 2019, 20(20)

Berry S E, Kinsella T J. Targeting DNA mismatch repair for radiosensitization [J]. Semin Radiat Oncol, 2001, 11(4): 300-315.

Stewart D J. Mechanisms of resistance to cisplatin and carboplatin [J]. Crit Rev Oncol Hematol, 2007, 63(1): 12-31.

Li Z H, Qiu M Z, Zeng Z L, et al. Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC) [J]. J Transl Med, 2012, 10: 21.

Kim E S, Tang X, Peterson D R, et al. Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer [J]. Lung Cancer, 2014, 85(1): 88-93.

Vazquez A, Kamphorst J J, Markert E K, et al. Cancer metabolism at a glance [J]. J Cell Sci, 2016, 129(18): 3367-3373.

Tzogani K, Penttilä K, Lapveteläinen T, et al. EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes [J]. Oncologist, 2020, 25(9): e1414-e1420.

Obrist F, Michels J, Durand S, et al. Metabolic vulnerability of cisplatin-resistant cancers [J]. Embo j, 2018, 37(14)

Siddik Z H. Cisplatin: mode of cytotoxic action and molecular basis of resistance [J]. Oncogene, 2003, 22(47): 7265-7279.

Sarin N, Engel F, Kalayda G V, et al. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest [J]. PLoS One, 2017, 12(7): e0181081.

Lu H, Xie X, Wang K, et al. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells [J]. Mol Cell Biochem, 2020, 475(1-2): 63-77.

Anderson N M, Simon M C. The tumor microenvironment [J]. Curr Biol, 2020, 30(16): R921-r925.

Zhang W, Ke Y, Liu X, et al. Drug resistance in NSCLC is associated with tumor micro-environment [J]. Reprod Biol, 2022, 22(3): 100680.

Saw P E, Chen J, Song E. Targeting CAFs to overcome anticancer therapeutic resistance [J]. Trends Cancer, 2022, 8(7): 527-555.

Suzuki J, Tsuboi M, Ishii G. Cancer-associated fibroblasts and the tumor microenvironment in non-small cell lung cancer [J]. Expert Rev Anticancer Ther, 2022, 22(2): 169-182.

Park S H, Seong M A, Lee H Y. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells [J]. Oncotarget, 2016, 7(7): 8184-8199.

Xu F, Gu J, Lu C, et al. Calpain-2 Enhances Non-Small Cell Lung Cancer Progression and Chemoresistance to Paclitaxel via EGFR-pAKT Pathway [J]. Int J Biol Sci, 2019, 15(1): 127-137.

Yuwen D, Ma Y, Wang D, et al. Prognostic Role of Circulating Exosomal miR-425-3p for the Response of NSCLC to Platinum-Based Chemotherapy [J]. Cancer Epidemiol Biomarkers Prev, 2019, 28(1): 163-173.

Si W, Shen J, Zheng H, et al. The role and mechanisms of action of microRNAs in cancer drug resistance [J]. Clin Epigenetics, 2019, 11(1): 25.

Huang R S, Zheng Y L, Zhao J, et al. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling [J]. Biomed Pharmacother, 2018, 98: 538-544.

Colín-Val Z, Flores-Navarro G, Rocha-Zavaleta L, et al. Fine particulate matter (PM (2.5)) promotes chemoresistance and aggressive phenotype of A549 lung cancer cells [J]. Toxicol Appl Pharmacol, 2024, 487: 116955.

Sun L, Liu H, Ye Y, et al. Smart nanoparticles for cancer therapy [J]. Signal Transduct Target Ther, 2023, 8(1): 418.

Yang Y, Bedford M T. Protein arginine methyltransferases and cancer [J]. Nat Rev Cancer, 2013, 13(1): 37-50.

Bedford M T. Arginine methylation at a glance [J]. J Cell Sci, 2007, 120(Pt 24): 4243-4246.

Niewmierzycka A, Clarke S. S-Adenosylmethionine-dependent methylation in Saccharomyces cerevisiae. Identification of a novel protein arginine methyltransferase [J]. J Biol Chem, 1999, 274(2): 814-824.

Motolani A, Martin M, Sun M, et al. Phosphorylation of the Regulators, a Complex Facet of NF-κB Signaling in Cancer [J]. Biomolecules, 2020, 11(1)

Lee J H, Cook J R, Yang Z H, et al. PRMT7, a new protein arginine methyltransferase that synthesizes symmetric dimethylarginine [J]. J Biol Chem, 2005, 280(5): 3656-3664.

Zurita-Lopez C I, Sandberg T, Kelly R, et al. Human protein arginine methyltransferase 7 (PRMT7) is a type III enzyme forming ω-NG-monomethylated arginine residues [J]. J Biol Chem, 2012, 287(11): 7859-7870.

Tan L, Xiao K, Ye Y, et al. High PRMT5 expression is associated with poor overall survival and tumor progression in bladder cancer [J]. Aging (Albany NY), 2020, 12(9): 8728-8741.

He L, Hu Z, Sun Y, et al. PRMT1 is critical to FEN1 expression and drug resistance in lung cancer cells [J]. DNA Repair (Amst), 2020, 95: 102953.

Gao Y, Feng C, Ma J, et al. Protein arginine methyltransferases (PRMTs): Orchestrators of cancer pathogenesis, immunotherapy dynamics, and drug resistance [J]. Biochem Pharmacol, 2024, 221: 116048.

Jing P, Xie N, Zhu X, et al. The methylation induced by protein arginine methyltransferase 5 promotes tumorigenesis and progression of lung cancer [J]. J Thorac Dis, 2018, 10(12): 7014-7019.

Sheng X, Bowen N, Wang Z. GLI pathogenesis-related 1 functions as a tumor-suppressor in lung cancer [J]. Mol Cancer, 2016, 15: 25.

Jing P, Zhao N, Ye M, et al. Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling [J]. Cancer Lett, 2018, 427: 38-48.

Huang J, Zheng Y, Zheng X, et al. PRMT5 Promotes EMT Through Regulating Akt Activity in Human Lung Cancer [J]. Cell Transplant, 2021, 30: 9636897211001772.

Zhang S, Ma Y, Hu X, et al. Targeting PRMT5/Akt signalling axis prevents human lung cancer cell growth [J]. J Cell Mol Med, 2019, 23(2): 1333-1342.

Zhou H, Chang J, Zhang J, et al. PRMT5 activates KLF5 by methylation to facilitate lung cancer [J]. J Cell Mol Med, 2023, 28(5): e17856.

Owens J L, Beketova E, Liu S, et al. PRMT5 Cooperates with pICln to Function as a Master Epigenetic Activator of DNA Double-Strand Break Repair Genes [J]. iScience, 2020, 23(1): 100750.

Shen Q, Liu Y, Deng X, et al. PRMT5 promotes chemotherapy-induced neuroendocrine differentiation in NSCLC [J]. Thorac Cancer, 2023, 14(18): 1764-1773.

Xu J, Wang Z. Recent advances progress of targeted drugs combined with radiotherapy for advanced non-small cell lung cancer: a review [J]. Front Oncol, 2023, 13: 1285593.

Lu W, Yao J, Zhu X, et al. Nanomedicines: Redefining traditional medicine [J]. Biomed Pharmacother, 2021, 134: 111103.

Chen D, Liu X, Lu X, et al. Nanoparticle drug delivery systems for synergistic delivery of tumor therapy [J]. Front Pharmacol, 2023, 14: 1111991.

Haider M, Elsherbeny A, Pittalà V, et al. Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer [J]. Int J Mol Sci, 2022, 23(3)

Feng Q, Chen J, Huang J, et al. A redox-responsive nanosystem to suppress chemoresistant lung cancer through targeting STAT3 [J]. J Control Release, 2023, 363: 349-360.

Junwei, Li, DANDan, et al. A triple-combination nanotechnology platform based on multifunctional RNA hydrogel for lung cancer therapy [J]. 2020, 63(4): 8.

Chow E K, Ho D. Cancer nanomedicine: from drug delivery to imaging [J]. Sci Transl Med, 2013, 5(216): 216rv214.

Jiang W, Von Roemeling C A, Chen Y, et al. Designing nanomedicine for immuno-oncology [J]. 2017, 1(2): 0029.

Salvatorelli E, De Tursi M, Menna P, et al. Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis [J]. Drug Metab Dispos, 2012, 40(12): 2365-2373.

Hirsch F R, Scagliotti G V, Mulshine J L, et al. Lung cancer: current therapies and new targeted treatments [J]. Lancet, 2017, 389(10066): 299-311.

Sun C Y, Li Y Z, Cao D, et al. Rapamycin and trametinib: a rational combination for treatment of NSCLC [J]. Int J Biol Sci, 2021, 17(12): 3211-3223.

Gu X, Qiu Y, Lin M, et al. CuS Nanoparticles as a Photodynamic Nanoswitch for Abrogating Bypass Signaling To Overcome Gefitinib Resistance [J]. Nano Lett, 2019, 19(5): 3344-3352.

Ran L, Xiao J, Zhang W, et al. Tumor microenvironment-activated hollow vanadium-based nanoplatform for precise therapy of lung cancer through synergistically reversing cisplatin resistance [J]. 2024, 484

Zhang X K, Wang Q W, Xu Y J, et al. Co-delivery of cisplatin and oleanolic acid by silica nanoparticles-enhanced apoptosis and reverse multidrug resistance in lung cancer [J]. Kaohsiung J Med Sci, 2021, 37(6): 505-512.

Mendes B B, Conniot J, Avital A, et al. Nanodelivery of nucleic acids [J]. Nat Rev Methods Primers, 2022, 2

Kotmakçı M, Çetintaş V B, Kantarcı A G. Preparation and characterization of lipid nanoparticle/pDNA complexes for STAT3 downregulation and overcoming chemotherapy resistance in lung cancer cells [J]. Int J Pharm, 2017, 525(1): 101-111.

Su W P, Cheng F Y, Shieh D B, et al. PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells [J]. Int J Nanomedicine, 2012, 7: 4269-4283.

Nascimento A V, Singh A, Bousbaa H, et al. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles [J]. Acta Biomater, 2017, 47: 71-80.

Brehmer D, Beke L, Wu T, et al. Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity [J]. Mol Cancer Ther, 2021, 20(12): 2317-2328.

Engstrom L D, Aranda R, Waters L, et al. MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer [J]. Cancer Discov, 2023, 13(11): 2412-2431.

Cottrell K M, Briggs K J, Whittington D A, et al. Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with MTAP-Deleted Cancers [J]. J Med Chem, 2024, 67(8): 6064-6080.